Compass Therapeutics (NASDAQ:CMPX) Price Target Raised to $12.00

Compass Therapeutics (NASDAQ:CMPX) had its target price increased by stock analysts at Guggenheim from $10.00 to $12.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 287.10% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Raymond James Financial upgraded shares of Compass Therapeutics to an “outperform” rating and set a $9.00 price target on the stock in a report on Tuesday, July 1st. D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Monday, April 28th. Finally, HC Wainwright restated a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Compass Therapeutics has a consensus rating of “Buy” and a consensus target price of $12.89.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $3.10 on Tuesday. The firm has a market cap of $428.67 million, a price-to-earnings ratio of -6.89 and a beta of 1.49. Compass Therapeutics has a 1 year low of $1.14 and a 1 year high of $4.08. The firm’s 50 day moving average price is $2.78 and its two-hundred day moving average price is $2.50.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, equities analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently bought and sold shares of the business. MPM Bioimpact LLC lifted its holdings in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after buying an additional 2,926,002 shares during the period. Enavate Sciences GP LLC acquired a new stake in Compass Therapeutics in the fourth quarter worth $11,293,000. Tang Capital Management LLC raised its holdings in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the period. Rock Springs Capital Management LP raised its holdings in Compass Therapeutics by 2.7% in the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock worth $8,380,000 after purchasing an additional 150,336 shares during the period. Finally, Blue Owl Capital Holdings LP raised its holdings in Compass Therapeutics by 2.6% in the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock worth $4,284,000 after purchasing an additional 75,000 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.